Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseases.

about

Pitavastatin and carbohydrate metabolism: what is the evidence?Statins and mortality: the untold story.

P2860

Q30251801-B02A340D-C21E-4F31-A363-54DC15E8195A Q53645752-27262208-D227-4F33-9D5C-157DFBBB9A5B

P2860

Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseases.

Item

http://www.wikidata.org/entity/Q38208727

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Benefit-risk assessment of ros ...... clerosis and related diseases.

@en

type

Item

label

Benefit-risk assessment of ros ...... clerosis and related diseases.

@en

prefLabel

Benefit-risk assessment of ros ...... clerosis and related diseases.

@en

P1476

Benefit-risk assessment of ros ...... sclerosis and related diseases

@en

P2093

Christos V Rizos

http://www.w3.org/2001/XMLSchema#string

Michael S Kostapanos

http://www.w3.org/2001/XMLSchema#string

Moses S Elisaf

http://www.w3.org/2001/XMLSchema#string

P2860

Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Statin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting system

Effects of intensive glucose lowering in type 2 diabetes

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

P2888

s40264-014-0169-4

P304

481-500

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40264-014-0169-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Moses Elisaf

Michael S Kostapanos

C Rizos

P577

2014-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1014189623

http://www.w3.org/2001/XMLSchema#string

P698

24788803

http://www.w3.org/2001/XMLSchema#string

Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseases.

about

P2860

P2860

Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseases.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698